Safety and Immunogenicity of Anti–SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ Transplants
2021; American College of Physicians; Volume: 174; Issue: 9 Linguagem: Inglês
10.7326/m21-1341
ISSN1539-3704
AutoresOlivier Marion, Arnaud Del Bello, Florence Abravanel, Chloé Couat, Stanislas Faguer, Laure Esposito, Anne Laure Hébral, Jacques Izopet, Nassim Kamar,
Tópico(s)Polyomavirus and related diseases
ResumoLetters25 May 2021Safety and Immunogenicity of Anti–SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ TransplantsFREEOlivier Marion, MD, Arnaud Del Bello, MD, Florence Abravanel, PharmD, PhD, Chloé Couat, MSc, Stanislas Faguer, MD, PhD, Laure Esposito, MD, Anne Laure Hebral, MD, Jacques Izopet, PharmD, PhD, Nassim Kamar, MD, PhDOlivier Marion, MDToulouse Rangueil University Hospital, Paul Sabatier University, and INSERM UMR 1291, Toulouse Institute for Infectious and Inflammatory Disease (Infinity), Toulouse, FranceSearch for more papers by this author, Arnaud Del Bello, MDToulouse Rangueil University Hospital and Paul Sabatier University, Toulouse, FranceSearch for more papers by this author, Florence Abravanel, PharmD, PhDToulouse Purpan University Hospital, Paul Sabatier University, and INSERM UMR 1291, Toulouse Institute for Infectious and Inflammatory Disease (Infinity), Toulouse, FranceSearch for more papers by this author, Chloé Couat, MScToulouse Rangueil University Hospital, Toulouse, FranceSearch for more papers by this author, Stanislas Faguer, MD, PhDToulouse Rangueil University Hospital and Paul Sabatier University, Toulouse, FranceSearch for more papers by this author, Laure Esposito, MDToulouse Rangueil University Hospital, Toulouse, FranceSearch for more papers by this author, Anne Laure Hebral, MDToulouse Rangueil University Hospital, Toulouse, FranceSearch for more papers by this author, Jacques Izopet, PharmD, PhDToulouse Purpan University Hospital, Paul Sabatier University, and INSERM UMR 1291, Toulouse Institute for Infectious and Inflammatory Disease (Infinity), Toulouse, FranceSearch for more papers by this author, Nassim Kamar, MD, PhDToulouse Rangueil University Hospital, Paul Sabatier University, and INSERM UMR 1291, Toulouse Institute for Infectious and Inflammatory Disease (Infinity), Toulouse, FranceSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M21-1341 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Background: Recipients of solid organ transplant (SOT) are a high-risk group for severe SARS-CoV-2 infection. The mortality rate of patients with SOT during the COVID-19 pandemic has been reported to be approximately 20% (1). The anti–SARS-CoV-2 vaccines represent a hope to protect this population against this life-threatening infection.Objective: To assess the humoral response to messenger RNA (mRNA)–based vaccination in recipients of SOT.Methods: All patients with heart, kidney, liver, or pancreas transplants from the Midi-Pyrénées region (southwest France) are followed in our department. When the vaccination campaign started (7 January 2021), these patients were invited via text message, e-mail, or transplant patients' associations to be vaccinated. Patients were asked to register via a dedicated telephone number or website. They were vaccinated consecutively according to their registration date. According to the recommendations of the Francophone Society of Transplantation, anti–SARS-CoV-2 spike protein antibodies were monitored before and after vaccination. We used the SARS-CoV-2 total antibodies enzyme-linked immunosorbent assay test (Beijing Wantai Biological Pharmacy Enterprise) (80% of patients) or another validated anti–SARS-CoV-2 spike protein assay. According to French law (loi Jardé), anonymous retrospective studies do not require institutional review board approval.Findings: By 16 April 2021, 950 patients of the 2666 from our cohort had received at least 1 dose of an mRNA vaccine (BNT162b2 vaccine [Pfizer-BioNTech], n = 942; mRNA-1273 vaccine [Moderna], n = 8) and had anti–SARS-CoV-2 antibodies monitored. Fifty patients had vaccination without monitoring of antibodies, 80 patients are planned to be vaccinated within the next month, and 257 patients declined the vaccine. We had no feedback from the remaining 1329 patients.A total of 895 of the 950 patients had an available serologic screening just before the first injection. The prevalence of anti–SARS-CoV-2 antibodies was 2.1% (95% CI, 1.3% to 3.3%; n = 19 of 895). Only 5 of the 19 patients who were seropositive previously had symptomatic COVID-19. A total of 576 patients benefited from a second injection at day 28. The prevalence of anti–SARS-CoV-2 antibodies before the second injection was 6.4% (CI, 4.6% to 8.8%; n = 37 of 576).In 367 patients who had a 4-week follow-up after the second dose, the prevalence of anti–SARS-CoV-2 antibodies increased from 1.4% (CI, 0.4% to 3.2%; n = 5 of 367) at baseline to 6.3% (CI, 4.0% to 9.3%; n = 23 of 367) at day 28 and 33.8% (CI, 29.0% to 38.9%; n = 124 of 367) 1 month after the second dose (Figure). Characteristics of patients who were vaccinated with and without a 4-week follow-up after the second dose are presented in the Table.Figure. Prevalence of anti–SARS-CoV-2 antibodies at 4 wk after the second vaccine dose in all transplant patients and by type of organ transplant.Percentages with exact binomial 95% CIs are presented. Download figure Download PowerPoint Table Characteristics of Recipients of SOT With and Without a 4-Week Follow-up After 2-Dose Messenger RNA–Based VaccinationThe tolerance of mRNA vaccines was excellent, with no serious adverse events reported, except in 1 patient with a liver transplant who developed paresthesia of the lower limb. Kidney function and liver enzymes remained stable in recipients of kidney and liver transplants before and 28 days after the first dose (data not shown). One recipient of a kidney transplant presented 3 weeks after the first injection with a 50% increase in serum creatinine level related to drug-induced dehydration. The patient recovered after rehydration and reduction of diuretics. Only 1 patient, who had vaccination without the requested biological monitoring and who is not included in this report, had an acute cellular rejection.Discussion: In immunocompetent patients, mRNA vaccines have shown strong antibody response, even after a single dose (2). In immunocompromised patients, such as recipients of SOT, a weak humoral response to mRNA vaccines was reported. Boyarsky and colleagues (3) reported the appearance of specific antibodies in 17% of transplant recipients 3 weeks after a single dose of an mRNA vaccine. Recently, in a small series of patients with SOT, including mainly those who had a kidney transplant, anti–SARS-CoV-2 antibodies were detected in 37.5% to 58.8% of patients at 4 weeks after the second dose (4, 5). Our study, which included many patients with SOT, confirms a weak immunogenicity of mRNA vaccines in those who had a transplant. Recipients of liver transplant showed a better humoral response than recipients of other organs. Considering the good tolerance of mRNA vaccines, an increased antigen dose or a third vaccine dose can be proposed to improve the vaccination response in this specific population. In France, the French National Authority for Health has recently recommended offering a third dose to immunosuppressed patients.Further studies are required to assess both cellular and humoral responses to vaccines and to determine their long-term protective capacity. Meanwhile, enhanced barrier measures should be maintained, and vaccination of household members and close contacts is recommended.References1. Kates OS, Haydel BM, Florman SS, et al; UW COVID-19 SOT Study Team. COVID-19 in solid organ transplant: a multi-center cohort study. Clin Infect Dis. 2020. [PMID: 32766815] doi:10.1093/cid/ciaa1097 CrossrefGoogle Scholar2. Sahin U, Muik A, Derhovanessian E, et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2020;586:594-599. [PMID: 32998157] doi:10.1038/s41586-020-2814-7 CrossrefMedlineGoogle Scholar3. Boyarsky BJ, Werbel WA, Avery RK, et al. Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients. JAMA. 2021. [PMID: 33720292] doi:10.1001/jama.2021.4385 CrossrefGoogle Scholar4. Grupper A, Rabinowich L, Schwartz D, et al. Reduced humoral response to mRNA SARS-Cov-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus. Am J Transplant. 2021. [PMID: 33866672] doi:10.1111/ajt.16615 CrossrefGoogle Scholar5. Marinaki S, Adamopoulos S, Degiannis D, et al. Immunogenicity of SARS-CoV-2 BNT162b2 vaccine in solid organ transplant recipients [Letter]. Am J Transplant. 2021. [PMID: 33864722] doi:10.1111/ajt.16607 CrossrefMedlineGoogle Scholar Comments 0 Comments Sign In to Submit A Comment Author, Article, and Disclosure InformationAuthors: Olivier Marion, MD; Arnaud Del Bello, MD; Florence Abravanel, PharmD, PhD; Chloé Couat, MSc; Stanislas Faguer, MD, PhD; Laure Esposito, MD; Anne Laure Hebral, MD; Jacques Izopet, PharmD, PhD; Nassim Kamar, MD, PhDAffiliations: Toulouse Rangueil University Hospital, Paul Sabatier University, and INSERM UMR 1291, Toulouse Institute for Infectious and Inflammatory Disease (Infinity), Toulouse, FranceToulouse Rangueil University Hospital and Paul Sabatier University, Toulouse, FranceToulouse Purpan University Hospital, Paul Sabatier University, and INSERM UMR 1291, Toulouse Institute for Infectious and Inflammatory Disease (Infinity), Toulouse, FranceToulouse Rangueil University Hospital, Toulouse, FranceDisclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M21-1341.Reproducible Research Statement: Study protocol: Available from Dr. Kamar (e-mail, kamar.n@chu-toulouse.fr). Statistical code and data set: Not available.Corresponding Author: Olivier Marion, MD, Toulouse Rangueil University Hospital, 1 Avenue du Professeur Jean Poulhès, Toulouse, France 31000; e-mail, marion.o@chu-toulouse.fr.This article was published at Annals.org on 25 May 2021. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byImpaired antibody response to inactivated COVID-19 vaccines in hospitalized patients with type 2 diabetesImmunogenicity of COVID ‐19 vaccines in chronic liver disease patients and liver transplant recipients: A systematic review and meta‐analysisImmunogenicity and Safety of the BNT162b2 COVID-19 Vaccine in Patients with Cystic Fibrosis with or without Lung TransplantationImmunogenicity of COVID-19 vaccines in solid organ transplant recipients: a systematic review and meta-analysisSARS-CoV-2 vaccine booster in solid organ transplant recipients previously immunised with inactivated versus mRNA vaccines: A prospective cohort studyCOVID-19 and kidney transplantationImmunogenicity of ChAdOx1 nCoV-19 vaccine after a two-dose inactivated SARS-CoV-2 vaccination of dialysis patients and kidney transplant recipientsThird COVID-19 vaccine dose boosts neutralizing antibodies in poor respondersEffect of age and rural residency on perceptions about SARS‐CoV‐2 pandemic and vaccination in kidney transplant recipientsWhat Is New in Prophylaxis and Treatment of COVID-19 in Renal Transplant Patients? A Report from an ESOT Meeting on the TopicHumoral and cellular immune responses to Pfizer-BioNTech BNT162b2 SARS-CoV-2 vaccine in adolescents with liver transplantation: Single center experienceImmunogenicity of COVID-19 mRNA vaccines in patients with acute myeloid leukemia and myelodysplastic syndromeFully understanding the efficacy profile of the COVID-19 vaccination and its associated factors in multiple real-world settingsImpact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paperThe risk and consequences of breakthrough SARS-CoV-2 infection in solid organ transplant recipients relative to non-immunosuppressed controlsCOVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysisCOVID-19 Vaccines against Omicron Variant: Real-World Data on EffectivenessmRNA Vaccine Effectiveness Against Coronavirus Disease 2019 Hospitalization Among Solid Organ Transplant RecipientsEfficacy and safety of SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive and biological therapy: Prospective observational studyCOVID-19 Vaccine Efficacy and Immunogenicity in End-Stage Renal Disease Patients and Kidney Transplant RecipientsEvolution of Clinical Care in COVID-Infected Solid Organ Transplant RecipientsImmunosuppressed non-responders to two doses of mRNA SARS-CoV-2 vaccines achieve an immune response comparable to those of immunocompetent individuals after a third doseMatched Versus Mixed COVID-19 Vaccinations in Korean Solid Organ Transplant Recipients: An Observational StudyCan the COVID-19 Pandemic Improve the Management of Solid Organ Transplant Recipients?Serological Response and Clinical Protection of Anti-SARS-CoV-2 Vaccination and the Role of Immunosuppressive Drugs in a Cohort of Kidney Transplant PatientsReduced Immune Response to Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Cohort of Immunocompromised Patients in ChileMycophenolate mofetil decreases humoral responses to three doses of SARS‐CoV ‐2 vaccine in liver transplant recipientsSafety Profile and Outcomes of Early COVID-19 Treatments in Immunocompromised Patients: A Single-Centre Cohort StudyAnalysis of the Specific Immune Response after the Third Dose of mRNA COVID-19 Vaccines in Organ Transplant Recipients: Possible Spike-S1 Reactive IgA Signature in Protection from SARS-CoV-2 InfectionSeroconversion rate after primary vaccination with two doses of BNT162b2 versus mRNA-1273 in solid organ transplant recipients: a systematic review and meta-analysisAssociation Between SARS-CoV-2 Messenger RNA Vaccines and Lower Infection Rates in Kidney Transplant Recipients A Registry-Based ReportIvan Zahradka, MD, Vojtech Petr, MD, Istvan Modos, MSc, PhD, Maria Magicova, MD, Ladislav Dusek, PhD, and Ondrej Viklicky, MD, PhDThe Global Impact of COVID-19 on Solid Organ Transplantation: Two Years Into a PandemicPrediction of Vaccine Response and Development of a Personalized Anti-SARS-CoV-2 Vaccination Strategy in Kidney Transplant Recipients: Results from a Large Single-Center StudyHemodynamic effects of COVID-19 vaccination in hospitalized patients awaiting heart transplantationMission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort StudiesSars‐Cov ‐2 vaccination in liver transplant recipients: The ‘holy grail’ in a hostile environmentPulmonary Embolism after Moderna Vaccination in Kidney Transplant Patients: Two Case Reports and Literature ReviewEffectiveness and Durability of mRNA Vaccine-Induced SARS-CoV-2-Specific Humoral and Cellular Immunity in Severe Asthma Patients on Biological TherapyCoronavirus disease 2019 and the liverAnti-SARS-CoV-2 spike protein and neutralizing antibodies at 1 and 3 months after three doses of SARS-CoV-2 vaccine in a large cohort of solid organ transplant patientsHumoral Response of Patients With Autoimmune Rheumatic Disease to BNT162b2 Vaccine: A Retrospective Comparative StudyImmunogenicity and Risk Factors Associated With Poor Humoral Immune Response of SARS-CoV-2 Vaccines in Recipients of Solid Organ TransplantCOVID-19 et transplantation d’organes, les leçons du recensement national de la Société francophone de transplantationSARS‐CoV‐2 vaccine clinical efficacy in SOT: What we know and our current gapsImmunogenicity and Safety of COVID-19 Vaccines in Patients Receiving Renal Replacement Therapy: A Systematic Review and Meta-AnalysisHumoral Immune Response to COVID-19 Vaccination in Hemodialysis Patients: A Retrospective, Observational Case–Control Pilot StudySARS-CoV-2 Vaccines: Safety and Immunogenicity in Solid Organ Transplant Recipients and Strategies for Improving Vaccine ResponsesEfficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trialSARS-CoV-2-specific humoral and cell-mediated immune responses after immunization with inactivated COVID-19 vaccine in kidney transplant recipients (CVIM 1 study)Humoral and Cellular Immune Responses of Solid Organ Transplant Patients on Belatacept to Three Doses of mRNA-Based Anti-SARS-CoV-2 VaccineReturn to School and COVID-19 Vaccination for Pediatric Solid Organ Transplant Recipients in the United States: Expert Opinion for 2021-2022Decline in Antibody Concentration 6 Months After Two Doses of SARS-CoV-2 BNT162b2 Vaccine in Solid Organ Transplant Recipients and Healthy ControlsUniversal Use of N95 Respirators in Healthcare Settings When Community Coronavirus Disease 2019 Rates Are HighInsight into the Advances in Clinical Trials of SARS-CoV-2 VaccinesAssociation Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the USImmunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic reviewImmunological Biomarkers in Blood to Monitor the Course and Therapeutic Outcomes of COVID-19Head-to-Head Comparison of Response Rates to the Two mRNA SARS-CοV-2 Vaccines in a Large Cohort of Solid Organ Transplant (SOT) RecipientsHumoral immunity against SARS‐CoV‐2 variants including omicron in solid organ transplant recipients after three doses of a COVID‐19 mRNA vaccinePredictive Factors for Humoral Response After 2-dose SARS-CoV-2 Vaccine in Solid Organ Transplant PatientsComparison of the Immune Response After an Extended Primary Series of COVID-19 Vaccination in Kidney Transplant Recipients Receiving Standard Versus Mycophenolic Acid–sparing Immunosuppressive RegimenPredictors of Nonseroconversion to SARS-CoV-2 Vaccination in Kidney Transplant RecipientsEfficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipientsCoordinated cellular and humoral immune responses after two‐dose SARS‐CoV2 mRNA vaccination in liver transplant recipientsRisk Factors Associated With SARS-CoV-2 Breakthrough Infections in Fully mRNA-Vaccinated Individuals: Retrospective AnalysisEfficacy and Safety of Third Dose of the COVID-19 Vaccine among Solid Organ Transplant Recipients: A Systemic Review and Meta-AnalysisWaning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 MonthsSevere Acute Respiratory Syndrome Coronavirus 2 Infection Induces Greater T-Cell Responses Compared to Vaccination in Solid Organ Transplant RecipientsClinical Considerations During Breakthrough Coronavirus Disease 2019 Infections in Vaccinated Individuals With AutoimmunityHumoral response to SARS-CoV-2 is well preserved and symptom dependent in kidney transplant recipientsAntibody response to two doses of inactivated SARS‐CoV‐2 vaccine (CoronaVac) in kidney transplant recipientsHumoral Immune Response following SARS-CoV-2 Vaccination in Liver Transplant RecipientsCOVID-19 Vaccine Booster Hesitancy (VBH) of Healthcare Workers in Czechia: National Cross-Sectional StudyCOVID ‐19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of CardiologyImpfstoffe gegen COVID-19A third injection of the BNT162b2 mRNA COVID-19 vaccine in kidney transplant recipients improves the humoral immune responseVaccination against COVID-19 for hematologic patients: A review of clinical guidelinesImmunological responses to SARS-CoV-2 vaccines in kidney transplant recipientsThe Case for Mandating COVID-19 Vaccines for Health Care WorkersMichael Klompas, MD, MPH, Madelyn Pearson, DNP, RN, and Charles Morris, MD, MPHReview of Early Immune Response to SARS-CoV-2 Vaccination Among Patients With CKDHigh immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patientsThree Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant RecipientsCOVID-19 in liver transplant recipients September 2021Volume 174, Issue 9 Page: 1336-1338 Keywords Antibodies COVID-19 Disclosure Liver transplantation Messenger RNA Proteins Renal transplantation Statistical data Transplantation Vaccines ePublished: 25 May 2021 Issue Published: September 2021 Copyright & PermissionsCopyright © 2021 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Referência(s)